The FDA has issued a complete response letter for Scholar Rock’s apitegromab SMA treatment following inspection failures and ongoing quality-control issues at a Novo Nordisk-owned contract manufacturing site, including pest contamination. The drug’s approval is delayed pending remediation, with no timeline for resubmission. This setback interrupts the company’s plan to deliver a novel treatment for spinal muscular atrophy, exacerbating challenges in manufacturing compliance.